Birdwatch Note
2024-10-28 16:47:24 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Les brevets cités par Mélenchon concernent tous des médicaments dans le domaine public depuis parfois des décennies et pour lesquels existent des dizaines de génériques… Tout comme le paracétamol vendu sous la marque Doliprane Opella est la filiale “génériques” de Sanofi https://en.m.wikipedia.org/wiki/Fexofenadine https://en.m.wikipedia.org/wiki/Bromhexine https://en.m.wikipedia.org/wiki/Ambroxol
Written by 80FE797B84B2394866EB4B2C667C548B0FBA9451517432F672BAD5F29C82EC49
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1850844885592498367
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1850942455782523175
- noteId - 1850942455782523175
- participantId -
- noteAuthorParticipantId - 80FE797B84B2394866EB4B2C667C548B0FBA9451517432F672BAD5F29C82EC49 Participant Details
- createdAtMillis - 1730134044963
- tweetId - 1850844885592498367
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Les brevets cités par Mélenchon concernent tous des médicaments dans le domaine public depuis parfois des décennies et pour lesquels existent des dizaines de génériques… Tout comme le paracétamol vendu sous la marque Doliprane Opella est la filiale “génériques” de Sanofi https://en.m.wikipedia.org/wiki/Fexofenadine https://en.m.wikipedia.org/wiki/Bromhexine https://en.m.wikipedia.org/wiki/Ambroxol
Note Ratings
| rated at | rated by | |
| 2024-10-31 17:19:17 -0500 | Rating Details | |
| 2024-10-31 14:57:11 -0500 | Rating Details | |
| 2024-10-31 11:19:12 -0500 | Rating Details | |
| 2024-10-31 10:54:21 -0500 | Rating Details | |
| 2024-10-31 09:57:50 -0500 | Rating Details | |
| 2024-10-31 07:30:35 -0500 | Rating Details | |
| 2024-10-31 02:15:24 -0500 | Rating Details | |
| 2024-10-30 15:18:17 -0500 | Rating Details | |
| 2024-10-30 03:19:03 -0500 | Rating Details | |
| 2024-10-29 09:31:40 -0500 | Rating Details | |
| 2024-10-29 07:28:13 -0500 | Rating Details | |
| 2024-10-29 04:24:15 -0500 | Rating Details | |
| 2024-10-29 02:41:56 -0500 | Rating Details | |
| 2024-10-29 01:48:40 -0500 | Rating Details | |
| 2024-10-29 01:37:23 -0500 | Rating Details | |
| 2024-10-29 01:36:30 -0500 | Rating Details | |
| 2024-10-29 00:58:22 -0500 | Rating Details | |
| 2024-10-29 00:20:30 -0500 | Rating Details | |
| 2024-10-28 17:24:05 -0500 | Rating Details | |
| 2024-10-28 17:21:29 -0500 | Rating Details | |
| 2024-10-28 16:46:10 -0500 | Rating Details | |
| 2024-10-28 15:25:44 -0500 | Rating Details | |
| 2024-10-28 15:09:57 -0500 | Rating Details | |
| 2024-10-28 13:56:54 -0500 | Rating Details | |
| 2024-10-28 13:38:16 -0500 | Rating Details | |
| 2024-10-28 12:51:16 -0500 | Rating Details | |
| 2024-10-28 12:23:53 -0500 | Rating Details | |
| 2024-10-28 11:51:06 -0500 | Rating Details | |
| 2024-11-01 13:32:17 -0500 | Rating Details | |
| 2024-11-01 07:52:48 -0500 | Rating Details | |
| 2024-11-01 04:15:34 -0500 | Rating Details | |
| 2024-11-01 03:30:50 -0500 | Rating Details | |
| 2024-10-31 21:03:50 -0500 | Rating Details | |
| 2024-11-01 02:43:27 -0500 | Rating Details | |
| 2024-10-31 13:28:52 -0500 | Rating Details | |
| 2024-10-31 13:14:38 -0500 | Rating Details | |
| 2024-10-31 09:42:54 -0500 | Rating Details | |
| 2024-10-31 07:33:59 -0500 | Rating Details | |
| 2024-10-31 06:45:48 -0500 | Rating Details | |
| 2024-10-31 06:02:47 -0500 | Rating Details | |
| 2024-10-31 01:59:39 -0500 | Rating Details | |
| 2024-10-30 14:06:47 -0500 | Rating Details | |
| 2024-10-29 08:47:49 -0500 | Rating Details | |
| 2024-10-29 06:52:54 -0500 | Rating Details | |
| 2024-10-29 04:18:05 -0500 | Rating Details | |
| 2024-10-29 04:11:05 -0500 | Rating Details | |
| 2024-10-29 02:31:01 -0500 | Rating Details | |
| 2024-10-29 02:22:01 -0500 | Rating Details | |
| 2024-10-29 02:06:50 -0500 | Rating Details | |
| 2024-10-29 02:01:49 -0500 | Rating Details | |
| 2024-10-28 19:46:14 -0500 | Rating Details | |
| 2024-10-28 18:25:59 -0500 | Rating Details | |
| 2024-10-28 17:25:27 -0500 | Rating Details | |
| 2024-10-28 14:45:17 -0500 | Rating Details | |
| 2024-10-28 12:50:56 -0500 | Rating Details | |
| 2024-10-28 11:54:39 -0500 | Rating Details | |
| 2024-11-01 02:22:59 -0500 | Rating Details | |
| 2024-10-31 21:13:47 -0500 | Rating Details | |
| 2024-10-31 12:36:20 -0500 | Rating Details | |
| 2024-10-31 12:14:34 -0500 | Rating Details | |
| 2024-10-31 11:24:38 -0500 | Rating Details | |
| 2024-10-31 10:13:28 -0500 | Rating Details | |
| 2024-10-31 08:30:28 -0500 | Rating Details | |
| 2024-10-31 08:07:36 -0500 | Rating Details | |
| 2024-10-29 08:32:08 -0500 | Rating Details | |
| 2024-10-29 07:27:19 -0500 | Rating Details | |
| 2024-10-29 03:48:02 -0500 | Rating Details | |
| 2024-10-29 02:03:12 -0500 | Rating Details | |
| 2024-10-28 16:41:58 -0500 | Rating Details | |
| 2024-10-28 16:34:33 -0500 | Rating Details | |
| 2024-10-28 15:50:02 -0500 | Rating Details | |
| 2024-10-28 13:40:31 -0500 | Rating Details | |
| 2024-10-28 13:27:53 -0500 | Rating Details | |
| 2024-10-28 13:09:43 -0500 | Rating Details | |
| 2024-10-28 12:54:21 -0500 | Rating Details | |
| 2024-10-28 12:54:06 -0500 | Rating Details | |
| 2024-10-28 12:46:52 -0500 | Rating Details | |
| 2024-10-28 11:56:23 -0500 | Rating Details | |
| 2024-10-28 11:49:24 -0500 | Rating Details | |
| 2024-11-02 05:51:33 -0500 | Rating Details | |
| 2024-10-31 21:58:54 -0500 | Rating Details | |
| 2024-10-31 17:27:46 -0500 | Rating Details | |
| 2024-10-31 15:47:09 -0500 | Rating Details | |
| 2024-10-31 11:18:03 -0500 | Rating Details | |
| 2024-10-31 10:34:19 -0500 | Rating Details | |
| 2024-10-31 10:28:45 -0500 | Rating Details | |
| 2024-10-31 01:14:11 -0500 | Rating Details | |
| 2024-10-29 05:50:53 -0500 | Rating Details | |
| 2024-10-28 18:12:03 -0500 | Rating Details | |
| 2024-10-28 16:51:17 -0500 | Rating Details | |
| 2024-10-28 16:45:51 -0500 | Rating Details | |
| 2024-10-28 16:07:58 -0500 | Rating Details | |
| 2024-10-28 15:57:04 -0500 | Rating Details | |
| 2024-10-28 15:52:56 -0500 | Rating Details | |
| 2024-10-28 15:35:47 -0500 | Rating Details | |
| 2024-10-28 14:33:44 -0500 | Rating Details | |
| 2024-10-28 14:13:44 -0500 | Rating Details | |
| 2024-10-28 13:13:51 -0500 | Rating Details |